|
||||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ENSG00000106484 |
Summary for MEST |
Gene summary |
| Gene information | Ensembl ID | ENSG00000106484 | Gene symbol | MEST |
| Gene name | mesoderm specific transcript | |
| HGNC | 7028 | |
| Entrez ID | 4232 | |
| Gene type | protein_coding | |
| Synonyms | MEST|PEG1 | |
| UniProtAcc | Q5EB52 |
Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for MEST |
AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure.∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
Landscape of gene expressions across multiple cancer types. |
Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Differentially expressed gene analysis between tumor male and normal male samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| MEST | 4.41e+03 | 2.16e+00 | 3.97e-01 | 5.44e+00 | 5.46e-08 | 2.18e-06 | ESCA |
Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| MEST | 1.48e+03 | 1.31e+00 | 3.08e-01 | 4.25e+00 | 2.12e-05 | 1.55e-04 | HNSC |
| MEST | 3.53e+03 | -1.61e+00 | 1.20e-01 | -1.35e+01 | 2.03e-41 | 1.55e-40 | BRCA |
| MEST | 2.55e+03 | 1.34e+00 | 1.90e-01 | 7.05e+00 | 1.76e-12 | 7.51e-11 | READ |
Top |
Sex-biased somatic mutation for MEST |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for MEST |
Landscape of DNA methylation across multiple cancer types. |
Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg04029027 | chr7:130485970 | CGI:chr7:130486176-130486960 | promoter | 7.02e-01 | 5.14e-01 | 2.57e+00 | 1.00e-02 | 2.67e-02 | 1.88e-01 |
| BRCA | cg01793704 | chr7:130486183 | CGI:chr7:130486176-130486960 | UTR,promoter,exon,gene body | 2.29e-01 | 7.99e-02 | 2.66e+00 | 7.76e-03 | 2.43e-02 | 1.49e-01 |
| BRCA | cg16511229 | chr7:130486312 | CGI:chr7:130486176-130486960 | UTR,promoter,exon,gene body | 3.27e-01 | 1.92e-01 | 2.14e+00 | 3.20e-02 | 4.21e-02 | 1.35e-01 |
| BRCA | cg01888566 | chr7:130486672 | CGI:chr7:130486176-130486960 | promoter,gene body | 2.26e-01 | 8.85e-02 | 2.82e+00 | 4.82e-03 | 2.00e-02 | 1.37e-01 |
| BRCA | cg02490034 | chr7:130485995 | CGI:chr7:130486176-130486960 | promoter | 5.13e-01 | 3.44e-01 | 2.95e+00 | 3.16e-03 | 1.68e-02 | 1.68e-01 |
| BRCA | cg09059945 | chr7:130486177 | CGI:chr7:130486176-130486960 | UTR,promoter,exon,gene body | 2.89e-01 | 1.16e-01 | 2.77e+00 | 5.52e-03 | 2.12e-02 | 1.73e-01 |
| BRCA | cg02169391 | chr7:130486335 | CGI:chr7:130486176-130486960 | UTR,promoter,exon,gene body | 1.86e-01 | 7.94e-02 | 2.19e+00 | 2.82e-02 | 4.00e-02 | 1.06e-01 |
| BRCA | cg09872616 | chr7:130486341 | CGI:chr7:130486176-130486960 | UTR,promoter,exon,gene body | 3.67e-01 | 2.47e-01 | 2.40e+00 | 1.66e-02 | 3.25e-02 | 1.19e-01 |
| BRCA | cg08077673 | chr7:130486527 | CGI:chr7:130486176-130486960 | promoter,gene body | 3.29e-01 | 1.73e-01 | 2.79e+00 | 5.26e-03 | 2.08e-02 | 1.56e-01 |
| KIRP | cg01888566 | chr7:130486672 | CGI:chr7:130486176-130486960 | promoter,gene body | 2.40e-01 | 1.33e-01 | 3.61e+00 | 3.10e-04 | 1.98e-03 | 1.07e-01 |
| SARC | cg01888566 | chr7:130486672 | CGI:chr7:130486176-130486960 | promoter,gene body | 6.44e-01 | 4.97e-01 | 4.44e+00 | 9.01e-06 | 5.69e-05 | 1.47e-01 |
| SARC | cg09059945 | chr7:130486177 | CGI:chr7:130486176-130486960 | UTR,promoter,exon,gene body | 7.44e-01 | 6.36e-01 | 3.98e+00 | 6.78e-05 | 3.63e-04 | 1.08e-01 |
| ACC | cg04029027 | chr7:130485970 | CGI:chr7:130486176-130486960 | promoter | 5.48e-01 | 6.63e-01 | -2.23e+00 | 2.58e-02 | 3.92e-02 | -1.15e-01 |
| CHOL | cg04029027 | chr7:130485970 | CGI:chr7:130486176-130486960 | promoter | 6.57e-01 | 4.43e-01 | 2.71e+00 | 6.81e-03 | 1.64e-02 | 2.14e-01 |
| CHOL | cg20148994 | chr7:130485744 | CGI:chr7:130486176-130486960 | promoter | 8.33e-01 | 6.63e-01 | 2.48e+00 | 1.30e-02 | 2.54e-02 | 1.70e-01 |
Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| HNSC | cg04029027 | chr7:130485970 | CGI:chr7:130486176-130486960 | promoter | 5.99e-01 | 7.30e-01 | -2.43e+00 | 1.50e-02 | 1.81e-02 | -1.30e-01 |
| HNSC | cg22115706 | chr7:130485878 | CGI:chr7:130486176-130486960 | promoter | 7.24e-01 | 9.04e-01 | -3.02e+00 | 2.53e-03 | 3.99e-03 | -1.80e-01 |
| LUSC | cg04029027 | chr7:130485970 | CGI:chr7:130486176-130486960 | promoter | 4.47e-01 | 6.83e-01 | -3.78e+00 | 1.55e-04 | 8.53e-04 | -2.35e-01 |
| LUSC | cg18100127 | chr7:130485923 | CGI:chr7:130486176-130486960 | promoter | 4.73e-01 | 8.78e-01 | -2.07e+00 | 3.82e-02 | 4.01e-02 | -4.05e-01 |
| LUSC | cg07683330 | chr7:130485549 | CGI:chr7:130486176-130486960 | promoter | 6.85e-01 | 8.11e-01 | -4.04e+00 | 5.31e-05 | 5.65e-04 | -1.26e-01 |
| LUSC | cg20380768 | chr7:130485670 | CGI:chr7:130486176-130486960 | promoter | 4.64e-01 | 8.20e-01 | -4.39e+00 | 1.16e-05 | 5.26e-04 | -3.57e-01 |
| LUSC | cg20148994 | chr7:130485744 | CGI:chr7:130486176-130486960 | promoter | 6.19e-01 | 8.88e-01 | -4.27e+00 | 1.94e-05 | 5.26e-04 | -2.69e-01 |
| LUSC | cg22115706 | chr7:130485878 | CGI:chr7:130486176-130486960 | promoter | 6.22e-01 | 9.40e-01 | -3.20e+00 | 1.36e-03 | 3.20e-03 | -3.18e-01 |
| LUSC | cg02490034 | chr7:130485995 | CGI:chr7:130486176-130486960 | promoter | 3.58e-01 | 4.63e-01 | -2.97e+00 | 3.00e-03 | 5.60e-03 | -1.05e-01 |
| LUSC | cg15164103 | chr7:130487030 | CGI:chr7:130486176-130486960 | promoter,gene body | 2.64e-01 | 4.11e-01 | -3.83e+00 | 1.28e-04 | 7.80e-04 | -1.48e-01 |
| COAD | cg02490034 | chr7:130485995 | CGI:chr7:130486176-130486960 | promoter | 3.00e-01 | 4.62e-01 | -4.79e+00 | 1.69e-06 | 1.67e-05 | -1.61e-01 |
| COAD | cg15164103 | chr7:130487030 | CGI:chr7:130486176-130486960 | promoter,gene body | 2.55e-01 | 3.84e-01 | -4.50e+00 | 6.87e-06 | 4.46e-05 | -1.29e-01 |
| BLCA | cg07683330 | chr7:130485549 | CGI:chr7:130486176-130486960 | promoter | 7.07e-01 | 8.21e-01 | -3.38e+00 | 7.33e-04 | 1.78e-03 | -1.13e-01 |
| BLCA | cg20380768 | chr7:130485670 | CGI:chr7:130486176-130486960 | promoter | 5.75e-01 | 8.66e-01 | -4.27e+00 | 1.91e-05 | 1.36e-04 | -2.91e-01 |
| BLCA | cg22115706 | chr7:130485878 | CGI:chr7:130486176-130486960 | promoter | 7.72e-01 | 9.48e-01 | -2.51e+00 | 1.22e-02 | 1.66e-02 | -1.76e-01 |
| LIHC | cg02490034 | chr7:130485995 | CGI:chr7:130486176-130486960 | promoter | 2.92e-01 | 3.93e-01 | -4.79e+00 | 1.65e-06 | 5.71e-06 | -1.02e-01 |
| KIRP | cg01888566 | chr7:130486672 | CGI:chr7:130486176-130486960 | promoter,gene body | 1.33e-01 | 2.39e-01 | -3.86e+00 | 1.13e-04 | 2.87e-04 | -1.07e-01 |
| KIRP | cg05373657 | chr7:130486796 | CGI:chr7:130486176-130486960 | promoter,gene body | 1.69e-01 | 2.75e-01 | -4.51e+00 | 6.43e-06 | 2.57e-05 | -1.07e-01 |
| ESCA | cg20380768 | chr7:130485670 | CGI:chr7:130486176-130486960 | promoter | 4.33e-01 | 6.45e-01 | -2.02e+00 | 4.39e-02 | 4.78e-02 | -2.11e-01 |
| ESCA | cg02490034 | chr7:130485995 | CGI:chr7:130486176-130486960 | promoter | 3.69e-01 | 5.23e-01 | -2.00e+00 | 4.60e-02 | 4.84e-02 | -1.54e-01 |
| CHOL | cg20380768 | chr7:130485670 | CGI:chr7:130486176-130486960 | promoter | 5.80e-01 | 8.21e-01 | -2.21e+00 | 2.70e-02 | 3.50e-02 | -2.40e-01 |
Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg01888566 | chr7:130486672 | CGI:chr7:130486176-130486960 | promoter,gene body | 2.26e-01 | 3.29e-01 | -7.01e+00 | 2.44e-12 | 7.25e-12 | -1.03e-01 |
| BRCA | cg20380768 | chr7:130485670 | CGI:chr7:130486176-130486960 | promoter | 7.51e-01 | 8.76e-01 | -7.77e+00 | 7.55e-15 | 2.72e-14 | -1.25e-01 |
| BRCA | cg11865119 | chr7:130486091 | CGI:chr7:130486176-130486960 | promoter | 3.09e-01 | 4.57e-01 | -8.83e+00 | 1.09e-18 | 5.30e-18 | -1.48e-01 |
| BRCA | cg05373657 | chr7:130486796 | CGI:chr7:130486176-130486960 | promoter,gene body | 2.39e-01 | 3.41e-01 | -1.01e+01 | 8.50e-24 | 6.45e-23 | -1.02e-01 |
| BRCA | cg15164103 | chr7:130487030 | CGI:chr7:130486176-130486960 | promoter,gene body | 2.90e-01 | 4.37e-01 | -1.18e+01 | 4.78e-32 | 9.02e-31 | -1.47e-01 |
| HNSC | cg09425926 | chr7:130485130 | CGI:chr7:130486176-130486960 | promoter | 7.40e-01 | 8.40e-01 | -2.90e+00 | 3.79e-03 | 1.19e-02 | -1.00e-01 |
| LIHC | cg22115706 | chr7:130485878 | CGI:chr7:130486176-130486960 | promoter | 4.99e-01 | 9.06e-01 | -3.06e+00 | 2.25e-03 | 4.27e-03 | -4.07e-01 |
Top |
Exon skipping events with PSI in TCGA for MEST |
| ∗Please access ExonSkipDB for exon skipping annotation. |
Landscape of exon skipping events across multiple cancer types. |
Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for MEST |
| ∗Please access CAeditome for RNA editing annotation. |
Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for MEST |
TFs related to MEST.∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
MEST related gene.∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for MEST |
RBPs related to ES in MEST.∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| THYM | ENOX1 | exon_skip_471298 | 9.70e+00 | 9.80e-01 | 9.43e+00 | 1.73e-02 | Male-biased |
| COAD | KHDRBS2 | exon_skip_471305 | 1.00e+01 | 6.23e-03 | 1.04e+01 | 9.92e-01 | Female-biased |
| MESO | ENOX1 | exon_skip_471298 | 9.28e+00 | 3.88e-03 | 9.72e+00 | 9.94e-01 | Female-biased |
| MESO | PCBP2 | exon_skip_471296 | 8.04e+00 | 1.05e-02 | 8.38e+00 | 9.82e-01 | Female-biased |
MEST related ES.∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs10275649 | chr7:136229398:C:T | - | 0.161441115362473 | 0.0413134329830707 | GBM | Female-baised eQTL |
| rs2291566 | chr7:128842386:C:G | - | 0.242508109551566 | 0.049970906677589 | GBM | Female-baised eQTL |
| rs10280724 | chr7:130321022:A:T | - | -0.0366053692559465 | 0.0425285096193014 | THCA | Female-baised eQTL |
| rs112860389 | chr7:137111211:A:C | - | 0.231495013523943 | 0.030000882101947 | KIRP | Female-baised eQTL |
| rs371678913 | chr7:128577393:C:T | - | 0.0785775090658531 | 0.0280832463417428 | LUSC | Female-baised eQTL |
| rs77699733 | chr7:128697421:G:A | - | 0.068814898292209 | 0.0476328827110525 | LUSC | Female-baised eQTL |
| rs7793668 | chr7:131245643:G:C | - | 0.147920611785011 | 0.00121267768092502 | LGG | Female-baised eQTL |
| rs7797598 | chr7:131245977:G:C | - | 0.147920611785011 | 0.00121267768092502 | LGG | Female-baised eQTL |
| rs59129288 | chr7:131244894:A:G | - | 0.140667340246818 | 0.00368692739002442 | LGG | Female-baised eQTL |
| rs6963391 | chr7:121655272:T:C | - | 0.0693424840021405 | 0.0356359944602128 | LGG | Female-baised eQTL |
| rs10243173 | chr7:121644968:A:G | - | 0.0683425192520449 | 0.0398966305929943 | LGG | Female-baised eQTL |
| rs10238961 | chr7:121643997:A:C | - | 0.0682093515886643 | 0.0421225643987774 | LGG | Female-baised eQTL |
| rs1206370 | chr7:122081801:G:A | - | 0.122798454678122 | 0.0423849067861292 | LGG | Female-baised eQTL |
| rs1206371 | chr7:122082180:T:C | - | 0.122798454678122 | 0.0423849067861292 | LGG | Female-baised eQTL |
| rs13232539 | chr7:122092043:A:T | - | 0.125969784499044 | 0.0424701489767284 | LGG | Female-baised eQTL |
| rs279670 | chr7:122111662:G:T | - | 0.125969784499044 | 0.0424701489767284 | LGG | Female-baised eQTL |
| rs59353128 | chr7:121113235:A:G | - | 0.0624544159538099 | 0.0300548391855346 | KIRC | Female-baised eQTL |
| rs10230185 | chr7:121111345:A:C | - | 0.06254333741461 | 0.0336860259070667 | KIRC | Female-baised eQTL |
| rs60326700 | chr7:121115724:T:C | - | 0.06254333741461 | 0.0336860259070667 | KIRC | Female-baised eQTL |
| rs73433957 | chr7:121117512:C:T | - | 0.06254333741461 | 0.0336860259070667 | KIRC | Female-baised eQTL |
| rs2471287 | chr7:140278776:T:A | - | 0.0660362348086887 | 0.0442916427173597 | KIRC | Female-baised eQTL |
| rs10269374 | chr7:122495563:T:A | - | 0.0641447312307457 | 0.0497035721625618 | KIRC | Female-baised eQTL |
| rs10264820 | chr7:122503485:C:T | - | 0.0641447312307457 | 0.0497035721625618 | KIRC | Female-baised eQTL |
| rs12540818 | chr7:135847235:A:G | - | 0.0990699873319153 | 0.0302742919075777 | BLCA | Female-baised eQTL |
| rs6951752 | chr7:135864750:G:A | - | 0.0988925255235764 | 0.0309876444466724 | BLCA | Female-baised eQTL |
| rs10441386 | chr7:131142544:G:T | - | 0.0777725952596765 | 0.013607432321454 | LUAD | Female-baised eQTL |
Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs71541382 | chr7:138202865:C:T | - | 0.148504585401314 | 0.0131049632233965 | PCPG | Male-baised eQTL |
| rs79317600 | chr7:126336075:G:A | - | 0.0421600078808475 | 0.0320834755239906 | KIRC | Male-baised eQTL |
| rs78395051 | chr7:126200144:C:T | - | 0.0412214211183939 | 0.049240716301003 | KIRC | Male-baised eQTL |
| rs4732111 | chr7:135273190:G:T | - | -0.0693527977949222 | 0.0128405697003195 | COAD | Male-baised eQTL |
| rs7809734 | chr7:135267953:T:A | - | -0.0680796762379419 | 0.0158404986804634 | COAD | Male-baised eQTL |
| rs17168349 | chr7:135275888:C:T | - | -0.0649737683990848 | 0.0272426971493497 | COAD | Male-baised eQTL |
| rs292663 | chr7:135276595:T:C | - | 0.0639351429680742 | 0.0293749240819187 | COAD | Male-baised eQTL |
| rs7796553 | chr7:129740403:T:C | - | -0.0797387475986392 | 0.0332440542447294 | COAD | Male-baised eQTL |
| rs11766410 | chr7:135266058:T:C | - | -0.0624820025485243 | 0.0355861307171634 | COAD | Male-baised eQTL |
| rs292654 | chr7:135270099:G:T | - | -0.0604289660221462 | 0.0474582583055859 | COAD | Male-baised eQTL |
| rs292658 | chr7:135270746:A:G | - | -0.0604289660221462 | 0.0474582583055859 | COAD | Male-baised eQTL |
Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg16511229 | chr7:130486312 | gene,exon,promoter,UTR | -0.108244818305947 | 9.28823244863591e-10 | -0.47201081070837675 | 1.5104714048455918e-12 | KIRP |
| cg19386484 | chr7:130491868 | gene | -0.172321176804366 | 5.16778537227889e-11 | -0.4502753257935709 | 3.482056776371567e-14 | LUSC |
| cg12347392 | chr7:130491835 | gene | -0.206864169918183 | 1.13135892834863e-10 | -0.4356237455730379 | 5.040094889603629e-14 | LUSC |
| cg09003373 | chr7:130491154 | gene,enhancer | -0.1648243546788 | 1.82088956871086e-06 | -0.3452473728639534 | 3.820103043657225e-09 | LUSC |
| cg07224147 | chr7:130490912 | gene,enhancer | -0.164765928906253 | 1.84269139433639e-06 | -0.3451791481220284 | 4.108106453245575e-09 | LUSC |
| cg10249538 | chr7:130491988 | gene | -0.162193362269314 | 3.42120900460517e-06 | -0.3395937721818654 | 7.0765429422698096e-09 | LUSC |
| cg13986840 | chr7:130492612 | gene | -0.15537758960988 | 1.11288206391621e-05 | -0.32693616139511616 | 2.69206134341203e-08 | LUSC |
| cg20826277 | chr7:130490637 | gene,enhancer | -0.13191631152771 | 4.28655521694115e-10 | -0.40690134592335303 | 5.962241201259512e-13 | LGG |
| cg15068552 | chr7:130490362 | gene,enhancer | -0.100366939233144 | 5.00690863726073e-05 | -0.3016396010232172 | 1.7142586439093673e-07 | LGG |
Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg07224147 | chr7:130490912 | gene,enhancer | -0.3338813762867 | 6.26574254120999e-06 | -0.34987054029744524 | 2.742336803665023e-08 | LGG |
| cg14584935 | chr7:130490640 | gene,enhancer | -0.475425341518192 | 1.55867487428399e-24 | -0.7180324529672261 | 1.1530373705800302e-29 | SKCM |
| cg12070022 | chr7:130490348 | gene,enhancer | -0.467612118622188 | 1.10780516289284e-16 | -0.7493517565432051 | 7.118298208310889e-21 | BLCA |
| cg05222671 | chr7:130490314 | gene,enhancer | -0.468726393548961 | 2.42225556827863e-09 | -0.5562212704859388 | 3.0082905903370258e-12 | HNSC |
| cg12070022 | chr7:130490348 | gene,enhancer | -0.468726393548961 | 2.42225556827863e-09 | -0.5562212704859388 | 3.0082905903370258e-12 | HNSC |
| cg17347253 | chr7:130490447 | gene,enhancer | -0.468726393548961 | 2.42225556827863e-09 | -0.5562212704859388 | 3.0082905903370258e-12 | HNSC |
| cg26275543 | chr7:130490542 | gene,enhancer | -0.468726393548961 | 2.42225556827863e-09 | -0.5562212704859388 | 3.0082905903370258e-12 | HNSC |
Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of MEST |
Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000106484 | MEST | C0043094 | Weight Gain | 1 | CTD_human |